EGFR and non-small cell lung carcinoma: Given the incidence of EGFR mutations in NSCLC, and our data suggesting that mutations in mouse Ptprh resulted in increased EGFR activity, we hypothesized that PTPRH mutant human tumors would have increased EGFR signaling.